Trial record 1 of 1 for:    "Alzheimer disease type 3"
Previous Study | Return to List | Next Study

Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3

This study has been terminated.
(Postmarket study terminated as the SN6AD3 is no longer promoted.)
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00710905
First received: July 3, 2008
Last updated: November 21, 2011
Last verified: November 2011
  Purpose

The objective of this study is to prospectively evaluate the visual parameters in a series of patients after phacoemulsification cataract surgery in a series of patients bilaterally implanted with the AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) Models SN6AD1 And SN6AD3.


Condition Intervention Phase
Cataract
Device: AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Visual Function With Contralateral AcrySof® ReSTOR® Aspheric SN6AD1 and SN6AD3

Resource links provided by NLM:


Further study details as provided by Alcon Research:

Primary Outcome Measures:
  • Binocular Visual Acuity at Near, Intermediate and Distance [ Time Frame: 6 months after surgery ] [ Designated as safety issue: No ]
    Binocular uncorrected and best corrected visual acuity (VA) was tested at 4 meters (m) (distance), 60 centimeters (cm) (intermediate), and near at preferred distance (distance chosen by each subject and recorded in cm; mean and standard deviation calculated) with a standard ETDRS chart for distance and a hand held chart for near. Scores were calculated using logMAR values. LogMAR is the "logarithm of the minimum angle of resolution". A lower logMAR value indicates better VA.


Enrollment: 50
Study Start Date: October 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ReSTOR
Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, Acrysof ReSTOR +4 IOL in the other eye.
Device: AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3
Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prospective subjects should be 21 years of age and older, be of any race and gender and meet study entry criteria. Subject must require extraction of cataracts followed by implantation of a posterior chamber intraocular lens (IOL). Subjects must be candidates for bilateral removal of the natural crystalline lens followed by implantation of a multifocal IOL and be willing and able to complete all follow-up visits.

Exclusion Criteria:

  • Subjects with pre-existing conditions that could skew the results or are contraindications for the AcrySof® ReSTOR® IOL should be excluded from the study. Please consult the AcrySof® ReSTOR® Aspheric product inserts under "Precautions" for subject groups that should be excluded from this study.
  • All subjects must have ≤ 0.75 diopters of astigmatism preoperatively as measured by Keratometry (K) readings. If the surgeon determines that a correction of cylinder is necessary postoperatively, this may be performed after the three month evaluations are completed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00710905

Locations
Canada, British Columbia
Dr John Blaylock
Abbotsford, British Columbia, Canada, V2S 5A1
Canada, Quebec
Dr Dominique Meyer
Quebec City, Quebec, Canada, G1S 1X6
Sponsors and Collaborators
Alcon Research
Investigators
Principal Investigator: John Blaylock
  More Information

No publications provided

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00710905     History of Changes
Other Study ID Numbers: ALCONsur002.08
Study First Received: July 3, 2008
Results First Received: October 4, 2011
Last Updated: November 21, 2011
Health Authority: Canada: Health Canada

Keywords provided by Alcon Research:
Cataract IOL ReSTOR Aspheric
Bilateral cataract

Additional relevant MeSH terms:
Cataract
Lens Diseases
Eye Diseases

ClinicalTrials.gov processed this record on July 24, 2014